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Background
Tumors, including hematologic malignancies, can use the
PD-1 pathway to evade immune surveillance. Pembroli-
zumab, a highly selective, humanized monoclonal
antibody that blocks interaction of PD-1 with its ligands
PD-L1 and PD-L2, has demonstrated robust antitumor
activity and a manageable toxicity profile in advanced
solid tumors. In earlier data, pembrolizumab demon-
strated efficacy in Hodgkin lymphoma (HL)[1]. KEY-
NOTE-013 (ClinicalTrials.gov, NCT01953692) is a
multicenter, nonrandomized, open-label, multicohort
Phase Ib trial designed to assess safety and efficacy
of pembrolizumab in patients with hematologic
malignancies.
Methods
Cohorts include patients with intermediate-1, intermedi-
ate-2, or high-risk myelodysplastic syndrome (MDS) who
failed ≥4 cycles of prior treatment with a hypomethylating
agent; relapsed/refractory (R/R), multiple myeloma (MM)
who failed ≥2 lines of prior therapy, including a protea-
some inhibitor and IMiD; or R/R non-Hodgkin lymphoma
(NHL): primary mediastinal large B cell lymphoma
(MLBCL), follicular lymphoma (FL), diffuse large B cell
lymphoma (DLBCL), or any other PD-L1-positive NHL
that failed, was ineligible for, or refused a stem cell trans-
plant and R/R HL (not presented here). Key eligibility cri-
teria: age ≥18 years; ECOG PS 0/1; measurable disease;
adequate hematologic, renal, and hepatic function. Key
exclusion criteria: immunosuppressive disorder, active
autoimmune disease, active pneumonitis, prior anti-PD-1/
anti-PD-L1 therapy, active CNS involvement, and prior
allogeneic hematopoietic stem cell transplantation within
5 years). Pembrolizumab is given at 200 mg Q3W in
patients enrolled under the last amendment. Treatment
continues until disease progression or intolerable toxicity;
clinically stable patients may continue treatment beyond
radiographic or hematologic (MDS or MM) evidence of
progression until confirmed in following assessment. The
primary end point is objective response rate (ORR).
Secondary objectives include duration of response,
progression-free survival, overall survival, and association
between PD-L1 expression and response. Target enroll-
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